Investors shift attention to next generation of CAR-T, new sickle cell treatments at major hematology meeting
December 10, 2019 at 16:31 PM EST
A handful of sickle cell disease treatments and CAR-T therapies that treat cancer have been approved by the Food and Drug Administration in recent years, but a new crop of investigational therapies that would grow those markets is exciting investors.
